Source comparison
Selank GABA Mechanism Anxiolytic Action: Comparison to Conventional Anxiolytics
Primary Target GABA-A α2/β1 upregulation + enkephalinase inhibition Direct GABA-A positive allosteric modulation Serotonin reuptake inhibition 5-HT1A partial agonism Selank's multi-pathway action produces anxiolysis without sedation or tolerance. A profile non
This comparison does not assign a generated winner or score.
- Primary Target
- GABA-A α2/β1 upregulation + enkephalinase inhibition
- Direct GABA-A positive allosteric modulation
- Serotonin reuptake inhibition
- 5-HT1A partial agonism
- Selank's multi-pathway action produces anxiolysis without sedation or tolerance. A profile none of the conventional classes match
- Onset Timeline
- 12–24 hours for receptor expression changes; enkephalin effects within 2–4 hours
- 30–60 minutes
- 2–6 weeks
- 2–4 weeks
- The dual timeline (rapid enkephalin + delayed GABA upregulation) is unique. Neither purely acute nor purely chronic
- Sedation Risk
- Minimal to none in preclinical models
- Moderate to high, dose-dependent
- Minimal
- Selective α2 upregulation avoids the α1-mediated sedation that limits benzodiazepine use
- Tolerance Development
- None observed in chronic dosing studies
- Develops within 2–4 weeks of daily use
- None
- The transcriptional mechanism avoids receptor desensitisation. A critical advantage for chronic use scenarios
- Withdrawal Syndrome
- None documented in cessation studies
- Severe. Rebound anxiety, seizure risk
- Discontinuation syndrome possible
- Lack of direct receptor binding means no physical dependence. This is the clearest differentiator from benzodiazepines
- Cognitive Effects
- BDNF enhancement suggests pro-cognitive effects
- Impairs memory consolidation and psychomotor function
- Variable. Can improve or impair depending on baseline state
- Neutral
- The BDNF pathway suggests Selank may enhance cognition rather than impair it. The opposite of benzodiazepines